Cytokinetics Q1 net loss $161.4M; aficamten PDUFA extended to Dec 26, 2025

CYTOKINETICS INC

2025-Q1 EPS reported -$1.36 revenue$1,579,000

Net loss $161.4M ($1.36/share) vs $135.6M ($1.33/share) in Q1 2024; revenue $1.6M.
FDA extended aficamten PDUFA date for obstructive HCM to Dec 26, 2025 due to REMS submission; no additional clinical data requested.
MAPLE-HCM topline results expected May 2025; ACACIA-HCM enrollment completed, topline 1H 2026.
Cash, cash equivalents, and investments ~$1.1B at Mar 31, down $132.2M from Dec 31, 2024.
Full-year 2025 GAAP operating expense guidance maintained at $670-710M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.